> top > docs > PMC:7228307 > spans > 48031-48625 > annotations

PMC:7228307 / 48031-48625 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id tao:has_standard_notation
941 81-85 Gene denotes HER2 Gene:2064
942 119-123 Gene denotes HER2 Gene:2064
943 240-248 Gene denotes FcγRIIIa Gene:2214
944 326-333 Gene denotes FcγRIIb Gene:2213
945 487-491 Gene denotes HER2 Gene:13866
946 558-562 Gene denotes HER2 Gene:13866
947 368-372 Gene denotes FcγR Gene:2213
948 589-593 Species denotes mice Tax:10090
949 0-12 Chemical denotes Margetuximab MESH:C000617981
950 90-101 Chemical denotes trastuzumab MESH:D000068878
951 428-439 Chemical denotes trastuzumab MESH:D000068878
952 445-457 Chemical denotes margetuximab MESH:C000617981
953 135-142 Disease denotes cancers MESH:D009369
954 574-579 Disease denotes tumor MESH:D009369
955 182-187 Mutation denotes L235V p.L235V
956 189-194 Mutation denotes F243L p.F243L
957 196-201 Mutation denotes R292P p.R292P
958 203-208 Mutation denotes Y300L p.Y300L
959 213-218 Mutation denotes P396L p.P396L

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T390 169-180 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T391 493-498 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T89 19-23 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T90 474-478 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T91 574-579 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T827 38-40 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T828 240-242 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T829 326-328 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T830 361-362 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T831 368-370 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T832 493-507 http://purl.obolibrary.org/obo/CL_0001034 denotes cells in vitro

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T246 169-180 Chemical denotes amino acids http://purl.obolibrary.org/obo/CHEBI_33709
T247 169-174 Chemical denotes amino http://purl.obolibrary.org/obo/CHEBI_46882
T248 175-180 Chemical denotes acids http://purl.obolibrary.org/obo/CHEBI_37527

LitCovid-sample-PD-IDO

Id Subject Object Predicate Lexical cue
T224 493-498 http://purl.obolibrary.org/obo/CL_0000000 denotes cells

LitCovid-sample-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T53 169-180 Chemical denotes amino acids http://purl.obolibrary.org/obo/CHEBI_33709

LitCovid-sample-Pubtator

Id Subject Object Predicate Lexical cue pubann:denotes pubann:has_HGVS_notation
941 81-85 Gene denotes HER2 Gene:2064
942 119-123 Gene denotes HER2 Gene:2064
943 240-248 Gene denotes FcγRIIIa Gene:2214
944 326-333 Gene denotes FcγRIIb Gene:2213
945 487-491 Gene denotes HER2 Gene:13866
946 558-562 Gene denotes HER2 Gene:13866
947 368-372 Gene denotes FcγR Gene:2213
948 589-593 Species denotes mice Tax:10090
949 0-12 Chemical denotes Margetuximab MESH:C000617981
950 90-101 Chemical denotes trastuzumab MESH:D000068878
951 428-439 Chemical denotes trastuzumab MESH:D000068878
952 445-457 Chemical denotes margetuximab MESH:C000617981
953 135-142 Disease denotes cancers MESH:D009369
954 574-579 Disease denotes tumor MESH:D009369
955 182-187 Mutation denotes L235V p.L235V
956 189-194 Mutation denotes F243L p.F243L
957 196-201 Mutation denotes R292P p.R292P
958 203-208 Mutation denotes Y300L p.Y300L
959 213-218 Mutation denotes P396L p.P396L

LitCovid-sample-PD-NCBITaxon

Id Subject Object Predicate Lexical cue ncbi_taxonomy_id
T46 589-593 Species denotes mice NCBItxid:10095|NCBItxid:10088

LitCovid-sample-sentences

Id Subject Object Predicate Lexical cue
T278 0-379 Sentence denotes Margetuximab is an ADCC‐enhanced IgG1 Fc‐engineered variant of the approved anti‐HER2 mAb trastuzumab in phase III for HER2‐expressing cancers.66, 93 Alteration of five amino acids (L235V, F243L, R292P, Y300L and P396L) enhanced binding to FcγRIIIa which also had the additional effect of decreasing binding to the inhibitory FcγRIIb, and thereby increased its A‐to‐I FcγR ratio.
T279 380-594 Sentence denotes This was apparent when compared with unmodified trastuzumab the  margetuximab showed enhanced ADCC against HER2+ cells in vitro and demonstrated superior antitumor effects in an HER2‐expressing tumor model in mice.

LitCovid-sample-PD-FMA

Id Subject Object Predicate Lexical cue fma_id
T389 169-180 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T390 493-498 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646

LitCovid-sample-PD-GO-BP-0

Id Subject Object Predicate Lexical cue
T113 19-23 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T114 474-478 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC

LitCovid-sample-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T39 574-579 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070

LitCovid-sample-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T35 574-579 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664

LitCovid-sample-GO-BP

Id Subject Object Predicate Lexical cue
T113 19-23 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T114 474-478 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T113 19-23 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T114 474-478 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T278 0-379 Sentence denotes Margetuximab is an ADCC‐enhanced IgG1 Fc‐engineered variant of the approved anti‐HER2 mAb trastuzumab in phase III for HER2‐expressing cancers.66, 93 Alteration of five amino acids (L235V, F243L, R292P, Y300L and P396L) enhanced binding to FcγRIIIa which also had the additional effect of decreasing binding to the inhibitory FcγRIIb, and thereby increased its A‐to‐I FcγR ratio.
T279 380-594 Sentence denotes This was apparent when compared with unmodified trastuzumab the  margetuximab showed enhanced ADCC against HER2+ cells in vitro and demonstrated superior antitumor effects in an HER2‐expressing tumor model in mice.

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T35 574-579 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664